A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer
PHASE1CompletedINTERVENTIONAL
Enrollment
57
Participants
Timeline
Start Date
January 31, 2015
Primary Completion Date
September 30, 2019
Study Completion Date
April 30, 2020
Conditions
Advanced ER+, HER2-Negative Breast Cancer
Interventions
DRUG
Elacestrant
Trial Locations (1)
02451
Radius Pharmaceuticals, Inc., Waltham
All Listed Sponsors
lead
Stemline Therapeutics, Inc.
INDUSTRY
NCT02338349 - A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer | Biotech Hunter | Biotech Hunter